- Home
- HYMC vs CELC Comparison
HYMC vs CELC Comparison
Compare HYMC & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HYMC | CELC |
|---|---|---|
| Founded | N/A | 2011 |
| Country | United States | United States |
| Employees | 51 | N/A |
| Industry | Precious Metals | Medical Specialities |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.1B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | HYMC | CELC |
|---|---|---|
| Price | $32.47 | $108.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $107.88 |
| AVG Volume (30 Days) | ★ 3.6M | 602.7K |
| Earning Date | 03-03-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $706.83 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.30 | $7.58 |
| 52 Week High | $58.73 | $120.32 |
Technical Indicators
Market Signals| Indicator | HYMC | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 42.84 | 47.51 |
| Support Level | $30.67 | $99.22 |
| Resistance Level | $57.24 | $117.27 |
| Average True Range (ATR) | 3.17 | 6.15 |
| MACD | -0.96 | -0.55 |
| Stochastic Oscillator | 20.11 | 40.35 |
Price Performance
Historical ComparisonAbout HYMC Hycroft Mining Holding Corporation
Hycroft Mining Holding Corp is a United States-based gold and silver exploration-stage issuer. The company owns and is focused on developing its property, the Hycroft Mine, located northwest of Winnemucca, Nevada.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.